Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Work In Process (2016 - 2018)

Amicus Therapeutics' Work In Process history spans 3 years, with the latest figure at $7.2 million for Q1 2018.

  • For the quarter ending Q1 2018, Work In Process rose 107.46% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Mar 2018, up 107.46%, and an annual FY2017 reading of $3.8 million, up 16.17% over the prior year.
  • Work In Process for Q1 2018 was $7.2 million at Amicus Therapeutics, up from $3.8 million in the prior quarter.
  • The five-year high for Work In Process was $7.2 million in Q1 2018, with the low at $137000.0 in Q2 2016.
  • Average Work In Process over 3 years is $4.0 million, with a median of $3.6 million recorded in 2017.
  • Biggest YoY gain for Work In Process was 2643.07% in 2017; the steepest drop was 16.17% in 2017.
  • Tracing FOLD's Work In Process over 3 years: stood at $3.3 million in 2016, then grew by 16.17% to $3.8 million in 2017, then skyrocketed by 87.48% to $7.2 million in 2018.
  • Per Business Quant, the three most recent readings for FOLD's Work In Process are $7.2 million (Q1 2018), $3.8 million (Q4 2017), and $6.9 million (Q3 2017).